Active surveillance for prostate cancer
... You will return to a special clinic for the results of your biopsy. If the transperineal biopsy shows that the cancer is of a low enough a risk for you to be on an active surveillance programme, we will arrange shared-care follow up with your GP. Your PSA levels will need to be checked every six m ...
... You will return to a special clinic for the results of your biopsy. If the transperineal biopsy shows that the cancer is of a low enough a risk for you to be on an active surveillance programme, we will arrange shared-care follow up with your GP. Your PSA levels will need to be checked every six m ...
psa i love you: prostate cancer screening in ireland
... the advantages of PCa screening using PSA outweigh the risks. Although there is no organisation in Ireland that recommends widespread population based screening, many men still undergo PSA testing in a primary care setting. Ireland urgently needs guidelines for PSA screening based on current evidenc ...
... the advantages of PCa screening using PSA outweigh the risks. Although there is no organisation in Ireland that recommends widespread population based screening, many men still undergo PSA testing in a primary care setting. Ireland urgently needs guidelines for PSA screening based on current evidenc ...
Find more information at www.Prolaris.com
... Beneficiaries with localized prostate cancer. Your doctor ordered Prolaris to obtain more information about your prostate cancer tumor so he/she can more precisely tailor and recommend a treatment strategy based on your personal risk factors. Purpose: You may know your prostate-specific antigen (PSA ...
... Beneficiaries with localized prostate cancer. Your doctor ordered Prolaris to obtain more information about your prostate cancer tumor so he/she can more precisely tailor and recommend a treatment strategy based on your personal risk factors. Purpose: You may know your prostate-specific antigen (PSA ...
POLI-CHEMOTHERAPY, HORMONAL THERAPY AND IMMUNO
... gland respond well to hormone therapy or competitive inhibitors but the results are inconsistent depending on individual variability. Prostate gland epithelial malignant tumors in TNM stage I and II expressed the greatest responsiveness to therapeutic combinations of chemotherapy, nonspecific hormon ...
... gland respond well to hormone therapy or competitive inhibitors but the results are inconsistent depending on individual variability. Prostate gland epithelial malignant tumors in TNM stage I and II expressed the greatest responsiveness to therapeutic combinations of chemotherapy, nonspecific hormon ...
Localised Prostate Cancer - North West Urology Registrar Group
... 13,943 men <60 years Median PSA level was 0.7 aged 40-49 & 0.9 aged 50 to 59 Men <60, baseline PSA value between the age-specific median and 2.5 ng/mL was a significant predictor of later CaP and was associated with a significantly greater PSA velocity • A young man’s baseline PSA value was a strong ...
... 13,943 men <60 years Median PSA level was 0.7 aged 40-49 & 0.9 aged 50 to 59 Men <60, baseline PSA value between the age-specific median and 2.5 ng/mL was a significant predictor of later CaP and was associated with a significantly greater PSA velocity • A young man’s baseline PSA value was a strong ...
Prostate Cancer Screening 2012
... Healthy men should no longer receive a P.S.A. blood test to screen for prostate cancer because the test does not save lives over all and often leads to more tests and treatments that needlessly cause pain, impotence and incontinence in many, a key government health panel has decided. ...
... Healthy men should no longer receive a P.S.A. blood test to screen for prostate cancer because the test does not save lives over all and often leads to more tests and treatments that needlessly cause pain, impotence and incontinence in many, a key government health panel has decided. ...
Research Strategy - Prostate Cancer UK
... We believe that the foundations to help us distinguish clinically significant from insignificant cancers early in the diagnostic pathway already exist. So, in this area, the early focus of our Research Strategy will be on translational research. This is where we envisage building strong collaborativ ...
... We believe that the foundations to help us distinguish clinically significant from insignificant cancers early in the diagnostic pathway already exist. So, in this area, the early focus of our Research Strategy will be on translational research. This is where we envisage building strong collaborativ ...
Scottish Medicines Consortium approves Sanofi prostate cancer drug
... back to be with family and friends is highly important. The availability of Jevtana means men in Scotland now have an alternative effective treatment option. Likewise, physicians now have another medicine in their arsenal to treat patients.” In Scotland, nearly 1 in 2 men will be affected by some fo ...
... back to be with family and friends is highly important. The availability of Jevtana means men in Scotland now have an alternative effective treatment option. Likewise, physicians now have another medicine in their arsenal to treat patients.” In Scotland, nearly 1 in 2 men will be affected by some fo ...
Screening for Prostate Cancer - American College of Physicians
... Number that avoid death from prostate cancer because of screening ...
... Number that avoid death from prostate cancer because of screening ...
Prostate Cancer Molecular Subtypes and Biomarkers
... SPINK1 Over-expression of SPINK1 has been shown to be associated with poor outcome in ERG- prostate ...
... SPINK1 Over-expression of SPINK1 has been shown to be associated with poor outcome in ERG- prostate ...
Prostate cancer prophylaxis in high risk men
... Indication is for “high risk,” but was a “limited” high risk since some patients at high risk were excluded, so can these results be extrapolated to “all” high risk patients? Also I have concerns about the questions asked and objective of the study. The reduction was mostly in low grade [Gleasen < 7 ...
... Indication is for “high risk,” but was a “limited” high risk since some patients at high risk were excluded, so can these results be extrapolated to “all” high risk patients? Also I have concerns about the questions asked and objective of the study. The reduction was mostly in low grade [Gleasen < 7 ...
Patient Information What is the National Prostate Cancer Audit? Who
... Why have I been invited? Men who were diagnosed with prostate cancer in NHS hospitals in England are being sent a questionnaire at least 18 months after their cancer was diagnosed. Your hospital gave information about your prostate cancer diagnosis, treatment and outcomes to the National Cancer Regi ...
... Why have I been invited? Men who were diagnosed with prostate cancer in NHS hospitals in England are being sent a questionnaire at least 18 months after their cancer was diagnosed. Your hospital gave information about your prostate cancer diagnosis, treatment and outcomes to the National Cancer Regi ...
the wonders of medical inventions
... Prostate cancer is the third most common cancer among Singaporean men. Conventionally, it is diagnosed with the manual method, in which prostate tissue needed for biopsy, is obtained through the rectum. This can cause infection in one out of 20 patients. ...
... Prostate cancer is the third most common cancer among Singaporean men. Conventionally, it is diagnosed with the manual method, in which prostate tissue needed for biopsy, is obtained through the rectum. This can cause infection in one out of 20 patients. ...
Outline - OpenWetWare
... • Can be performed as an open procedure or laparoscopically +/- robotic assistance – No head to data comparing the approaches ...
... • Can be performed as an open procedure or laparoscopically +/- robotic assistance – No head to data comparing the approaches ...
Early evidence of anti-PD-1 activity in enzalutamide
... blockade in men with mCRPC. Although our study is limited by the small numbers of patients, the robust nature of these responses is notable, i.e. currently approved agents for mCRPC generally do not produce PSA reduction to ≤ 0.2 in the post-enzalutamide setting. Responses in liver metastases are al ...
... blockade in men with mCRPC. Although our study is limited by the small numbers of patients, the robust nature of these responses is notable, i.e. currently approved agents for mCRPC generally do not produce PSA reduction to ≤ 0.2 in the post-enzalutamide setting. Responses in liver metastases are al ...
Cosudex®50mg Fact Sheet - Prostate Cancer Foundation of Australia
... Cosudex® 50mg is used in combination with other medicines to treat advanced prostate cancer. Cosudex® 50mg belongs to the family of non-steroidal anti-androgens. Androgens such as testosterone are natural male sex hormones. In some types of prostate cancer, androgens may help the cancer cells grow. ...
... Cosudex® 50mg is used in combination with other medicines to treat advanced prostate cancer. Cosudex® 50mg belongs to the family of non-steroidal anti-androgens. Androgens such as testosterone are natural male sex hormones. In some types of prostate cancer, androgens may help the cancer cells grow. ...
prostate cancer
... ▸ When to start treatment ▸ What is initial treatment ? ▸ New treatments available ▸ Specific Problems and other Specialties ...
... ▸ When to start treatment ▸ What is initial treatment ? ▸ New treatments available ▸ Specific Problems and other Specialties ...
Active Surveillance in prostate cancer
... European Union from 2004 to 2006.4,5 Prostate cancer is the most frequently diagnosed form of cancer in men, accounting for 24,1% of all cases and is the third leading cause of death (10,4%) in men. Overall breast, prostate, colon and lung cancers are the most common forms of cancer. Together, they ...
... European Union from 2004 to 2006.4,5 Prostate cancer is the most frequently diagnosed form of cancer in men, accounting for 24,1% of all cases and is the third leading cause of death (10,4%) in men. Overall breast, prostate, colon and lung cancers are the most common forms of cancer. Together, they ...
